Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–814. doi:10.1001/jama.2014.732
   PubMed Web of Science ®Google Scholar
• Feng Z, Jianghua Z, Wang W. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis.[J]. Hepatology. 2019;70(4):1119–1133. doi:10.1002/hep.30702
   PubMedGoogle Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Wenjie D, Ye L, A L, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis.[J]. Medicine. 2017;96(39):e8179. doi:10.1097/MD.0000000000008179
   PubMedGoogle Scholar
• Brunt Elizabeth M, W-S WV, Nobili V, et al. Nonalcoholic fatty liver disease.[J]. Nat Rev Dis Primers. 2015;1:15080.
   PubMedGoogle Scholar
• C R MR, Watt Matthew J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509–520. doi:10.1038/nrendo.2017.56
   PubMedGoogle Scholar
• Ao N, Jing Y, Wang X, et al. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway.[J]. Hepatol Res. 2016;46(4):343–353. doi:10.1111/hepr.12551
   PubMed Web of Science ®Google Scholar
• Minoru I, Takumi K, et al. Dipeptidyl peptidase-4: a key player in chronic liver disease.[J]. World J Gastroenterol. 2013;19(15):2298–2306. doi:10.3748/wjg.v19.i15.2298
   PubMedGoogle Scholar
• Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol. 2007;6(4):242–250. doi:10.1016/S1665-2681(19)31905-2
   PubMed Web of Science ®Google Scholar
• Xin S, Kong Y, Daoquan P. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.[J]. Clin Chim Acta. 2019;498:30–37. doi:10.1016/j.cca.2019.08.005
   PubMedGoogle Scholar
• Kovalic Alexander J, Satapathy Sanjaya K, Naga C. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.[J]. Hepatol Int. 2018;12(2):97–106. doi:10.1007/s12072-018-9854-1
   PubMedGoogle Scholar
• Carbone Laura J, Angus Peter W, Yeomans Neville D. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(1):23–31. doi:10.1111/jgh.13026
   PubMedGoogle Scholar
• Juan-Juan L, Ping Z. The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.[J]. Rev Assoc Med Bras. 1992;2019(65):33–37.
   Google Scholar
• Wang Q, Guan XQ. Improvement of induction method of non-alcoholic fatty liver model in rats. Shijie Huaren Xiaohua Zazhi. 2007;15(11):1219–1224.
   Google Scholar
• J K C L, Zhang X, Yu J. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances[J]. J Pathol. 2017;1:154.
   Google Scholar
• Yoshio S, Yuya S, Yoneda M, et al. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.[J]. Hepatol Res. 2017;47(4):266–280. doi:10.1111/hepr.12856
   PubMedGoogle Scholar
• Browning Jeffrey D, Horton Jay D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147–152. doi:10.1172/JCI200422422
   PubMedGoogle Scholar
• Christian B, Luisa S, Saussenthaler S, et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease.[J]. Mol Metab. 2017;6(10):1254–1263. doi:10.1016/j.molmet.2017.07.016
   PubMedGoogle Scholar
• Ahmad H, Dyah P, Kalista Kemal F, et al. The influence of insulin resistance in the occurence of non-alcoholic fatty liver disease among first degree relatives of type 2 diabetes.[J]. Diabetes Metab Syndr. 2019;13(2):1431–1435. doi:10.1016/j.dsx.2019.01.058
   PubMedGoogle Scholar
• Katharina H, Pras-Raves Mia L, Ferdinandusse S, et al. Functional characterisation of peroxisomal β-oxidation disorders in fibroblasts using lipidomics.[J]. J Inherit Metab Dis. 2018;41(3):479–487. doi:10.1007/s10545-017-0076-9
   PubMedGoogle Scholar
• Yu-Pei Z, Yuan-Jun D, et al. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.[J]. Curr Med Sci. 2019;39(1):37–43. doi:10.1007/s11596-019-1997-3
   PubMedGoogle Scholar
• Sudhir K, Richa R, Karns R, et al. Augmenter of liver regeneration protein deficiency promotes hepatic steatosis by inducing oxidative stress and microRNA-540 expression.[J]. FASEB J. 2019;33(3):3825–3840. doi:10.1096/fj.201802015R
   PubMedGoogle Scholar
• Maja S-R, German P, Mantell Benjamin S, et al. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.[J]. Am J Physiol Endocrinol Metab. 2008;294(5):E969–77. doi:10.1152/ajpendo.00497.2007
   PubMedGoogle Scholar
• Cherkaoui-Malki M, Surapureddi S, El Hajj HI, Vamecq J, Andreoletti P. Hepatic steatosis and peroxisomal fatty acid beta-oxidation. Curr Drug Metab. 2012;13(10):1412–1421. doi:10.2174/138920012803762765
   PubMedGoogle Scholar
• Purnomo Hery D. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).[J]. Acta Med Indones. 2015;47:16–23.
   PubMedGoogle Scholar
• Lingyan Y, Zheng C, Lai X, et al. Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.[J]. J Nutr. 2019;1.
   Google Scholar
• Frank T, Tom L, Christian T. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol. 2009;36:4–12. doi:10.1007/s12016-008-8091-0
   PubMedGoogle Scholar
• Annie-Carole T-T, Landes Susan G, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.[J]. J Biol Chem. 2012;287(48):40161–40172. doi:10.1074/jbc.M112.417014
   PubMedGoogle Scholar
• Fen Z, Ni Y, Nagashimada M. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.[J]. Diabetes. 2016;65(10):2966–2979. doi:10.2337/db16-0317
   PubMedGoogle Scholar
• Jesse B, Haj Fawaz G. Protein-tyrosine phosphatase 1B substrates and metabolic regulation.[J]. Semin Cell Dev Biol. 2015;37:58–65. doi:10.1016/j.semcdb.2014.09.020
   PubMedGoogle Scholar
• Nicola A, Dambrino Robert J. Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance.[J]. Am J Physiol Regul Integr Comp Physiol. 2018;314(3):R478–R488. doi:10.1152/ajpregu.00287.2017
   PubMedGoogle Scholar
• Sanderson Schuyler O, Smyrk Thomas C. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.[J]. Am J Clin Pathol. 2005;123(4):503–509. doi:10.1309/1PX2LMPQUH1EE12U
   PubMedGoogle Scholar
• Cynthia L, Deborah V, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.[J]. J Hepatol. 2018;69(4):927–947. doi:10.1016/j.jhep.2018.06.008
   PubMedGoogle Scholar
• Mulvihill Erin E, Drucker Daniel J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.[J]. Endocr Rev. 2014;35:992–1019.
   PubMedGoogle Scholar
• Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One. 2010;5(8):e12226. doi:10.1371/journal.pone.0012226
   PubMed Web of Science ®Google Scholar
• Masayuki M, Masaki K. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.[J]. Mol Med Rep. 2012;5:729–733.
   PubMedGoogle Scholar
• Ghorpade Devram S, Lale O, Zheng Z, et al. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.[J]. Nature. 2018;555(7698):673–677. doi:10.1038/nature26138
   PubMedGoogle Scholar
• Yoshimasa A, Kanako K, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.[J]. Int J Clin Pract. 2019;73(5):e13335. doi:10.1111/ijcp.13335
   PubMedGoogle Scholar
• Golightly Larry K, Drayna Caitlin C, McDermott Michael T. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.[J]. Clin Pharmacokinet. 2012;51(8):501–514. doi:10.1007/BF03261927
   PubMedGoogle Scholar